Investigating Novel Biomarkers in Endometrial Cancer:  A Study on RT-qPCR and Immunohistochemistry

Rong  Li; Ying  Yan; Fei  Liu; Xiaoyu  Gao; Xianling  Fu; Luona  Hu; Yanhong  Li

doi:10.18502/ijaai.v24i6.20159

Rong Li Department of Obstetrics and Gynecology, Tangdu Hospital, Air Force Medical University, Xi’an, Shaanxi, China
Ying Yan Department of Obstetrics and Gynecology, Tangdu Hospital, Air Force Medical University, Xi’an, Shaanxi, China
Fei Liu Department of Obstetrics and Gynecology, Tangdu Hospital, Air Force Medical University, Xi’an, Shaanxi, China
Xiaoyu Gao Department of Obstetrics and Gynecology, Tangdu Hospital, Air Force Medical University, Xi’an, Shaanxi, China
Xianling Fu Department of Obstetrics and Gynecology, Tangdu Hospital, Air Force Medical University, Xi’an, Shaanxi, China
Luona Hu Department of Obstetrics and Gynecology, Tangdu Hospital, Air Force Medical University, Xi’an, Shaanxi, China
Yanhong Li Department of Obstetrics and Gynecology, Tangdu Hospital, Air Force Medical University, Xi’an, Shaanxi, China

DOI: https://doi.org/10.18502/ijaai.v24i6.20159

Keywords: Biomarkers; DLX5; Endometrial cancer; GATA6; HOXB9; Immunohistochemistry; NGR1; prognosis; qPCR; RT

Abstract

This study aimed to investigate the expression patterns of HOXB9, DLX5, NGR1, and GATA6 in endometrial cancer tissues compared to adjacent non-cancerous tissues.

Using RT-qPCR and immunohistochemistry, the researchers found significant upregulation of HOXB9, DLX5, and NGR1, and downregulation of GATA6 in endometrial cancer samples.

The biomarker expression levels correlated with clinicopathological features, and survival analysis revealed that high expression of HOXB9, DLX5, and NGR1 was associated with poorer prognosis, while high GATA6 expression indicated better outcomes.

These findings suggest that these biomarkers may play crucial roles in endometrial cancer development and progression, highlighting their potential as diagnostic, prognostic, and therapeutic targets.